TY - JOUR
T1 - Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer
AU - Singh, Manu Smriti
AU - Ramishetti, Srinivas
AU - Landesman-Milo, Dalit
AU - Goldsmith, Meir
AU - Chatterjee, Sushmita
AU - Palakuri, Ramesh
AU - Peer, Dan
N1 - Funding Information:
The authors thank Dr. Andrea Atzmon and Dr. Orna Elroy Stein for technical assistance with Puromycin incorporation assay. This work was supported in part by the Israel Science Foundation (ISF) grant #1178/16, the Rivkin Foundation, and Len and Susan Mark Program in Ovarian Cancer awarded to D.P.
Publisher Copyright:
© 2021 Wiley-VCH GmbH
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/5/12
Y1 - 2021/5/12
N2 - Ovarian cancer is an aggressive tumor owing to its ability to metastasize from stage II onward. Herein, lipid nanoparticles (LNPs) that encapsulate combination of small interfering RNAs (siRNAs), polo-like kinase-1 (PLK1), and eukaryotic translation-initiation factor 3c (eIF3c), to target different cellular pathways essential for ovarian cancer progression are generated. The LNPs are further modified with hyaluronan (tNPs) to target cluster of differentiation 44 (CD44) expressing cells. Interestingly, hyaluronan-coated LNPs (tNPs) prolong functional activity and reduce growth kinetics of spheroids in in vitro assay as compared to uncoated LNPs (uNPs) due to ≈1500-fold higher expression of CD44. Treatment of 2D and 3D cultured ovarian cancer cells with LNPs encapsulating both siRNAs result in 85% cell death and robust target gene silencing. In advanced orthotopic ovarian cancer model, intraperitoneal administration of LNPs demonstrates CD44 specific tumor targeting of tNPs compared to uNPs and robust gene silencing in tissues involved in ovarian cancer pathophysiology. At very low siRNA dose, enhanced overall survival of 60% for tNPs treated mice is observed compared to 10% and 20% for single siRNA-, eIF3c-tNP, and PLK1-tNP treatment groups, respectively. Overall, LNPs represent promising platform in the treatment of advanced ovarian cancer by improving median- and overall-survival.
AB - Ovarian cancer is an aggressive tumor owing to its ability to metastasize from stage II onward. Herein, lipid nanoparticles (LNPs) that encapsulate combination of small interfering RNAs (siRNAs), polo-like kinase-1 (PLK1), and eukaryotic translation-initiation factor 3c (eIF3c), to target different cellular pathways essential for ovarian cancer progression are generated. The LNPs are further modified with hyaluronan (tNPs) to target cluster of differentiation 44 (CD44) expressing cells. Interestingly, hyaluronan-coated LNPs (tNPs) prolong functional activity and reduce growth kinetics of spheroids in in vitro assay as compared to uncoated LNPs (uNPs) due to ≈1500-fold higher expression of CD44. Treatment of 2D and 3D cultured ovarian cancer cells with LNPs encapsulating both siRNAs result in 85% cell death and robust target gene silencing. In advanced orthotopic ovarian cancer model, intraperitoneal administration of LNPs demonstrates CD44 specific tumor targeting of tNPs compared to uNPs and robust gene silencing in tissues involved in ovarian cancer pathophysiology. At very low siRNA dose, enhanced overall survival of 60% for tNPs treated mice is observed compared to 10% and 20% for single siRNA-, eIF3c-tNP, and PLK1-tNP treatment groups, respectively. Overall, LNPs represent promising platform in the treatment of advanced ovarian cancer by improving median- and overall-survival.
KW - gene delivery
KW - lipid nanoparticle
KW - ovarian cancer
KW - small interfering RNA
KW - targeting
UR - http://www.scopus.com/inward/record.url?scp=85103612926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103612926&partnerID=8YFLogxK
U2 - 10.1002/smll.202100287
DO - 10.1002/smll.202100287
M3 - Article
C2 - 33825318
AN - SCOPUS:85103612926
SN - 1613-6810
VL - 17
JO - Small
JF - Small
IS - 19
M1 - 2100287
ER -